NATCO Pharma Limited: In-Depth Corporate Profile

Source: NATCO Pharma Limited Annual Report 2025-26.

Quick Facts / Company Snapshot

Source: NATCO Pharma Limited Annual Report 2025-26.

Company Overview

NATCO Pharma Limited is a research-driven, vertically integrated pharmaceutical and agrochemical company headquartered in Hyderabad, Telangana, India. Founded in 1981, the company has grown over four and a half decades from a single manufacturing facility into an international enterprise operating across regulated, semi-regulated, and emerging markets. The organization’s operational architecture encompasses the development, commercial synthesis, and marketing of Finished Dosage Formulations (FDF), Active Pharmaceutical Ingredients (APIs), and specialized crop protection solutions.

The organizational mission is centered on “Making specialty medicines accessible to all”. This purpose drives the business model toward targeting niche, technologically complex, and high-entry-barrier pharmaceutical therapies rather than commoditized generic medications. The corporate governance structure is anchored by six core values: Integrity, Respect, Openness, Creative, Collaborative, and Quality.

• Global Footprint: NATCO commercializes products in more than 50 countries, supported by 13 subsidiaries, 2 step-down subsidiaries, and 1 associate.
• Manufacturing Scale: The company operates nine manufacturing facilities in India (seven dedicated to pharmaceuticals and two to crop health sciences) alongside two research facilities.
• Workforce Scale: A team of over 5,200 personnel worldwide supports continuous production, research, and distribution activities.

The financial year 2025-26 represented a structural consolidation and transitional phase for NATCO. The business navigated the scheduled taper of its exclusivity-driven export earnings from generic Lenalidomide in the United States, which had driven historical revenue peaks. To mitigate reliance on single-market windfalls, executive leadership deployed capital to broaden its base business across five geographic pillars: India, the United States, Brazil, Canada, and South Africa.

A primary strategic event during the period was the acquisition of a 35.75% equity interest in Adcock Ingram Holdings Proprietary Limited—the second-largest pharmaceutical player by private market share in South Africa—which was subsequently raised to 49% in July 2026. This acquisition established an African commercial platform and helped elevate the combined Group revenue base beyond the US$1 billion mark.

Related Posts

V.S.T. Tillers Tractors Limited: In-Depth Corporate Profile, Financial and Key Brands

September 5, 2026

Kewal Kiran Clothing Limited: Profile, Killer Jeans, Brands & Financials

September 3, 2026

Hatsun Agro Product Limited: Corporate Profile, Business Segments, History, and Brand

September 3, 2026

Endurance Technologies Limited: Overview, Segments, History

September 3, 2026

Sharda Motor Industries Limited: Full In-Depth Corporate Profile

September 1, 2026

Aptech Limited: In-Depth Full Profile

August 30, 2026

Domestically, the company maintained its oncology market position while expanding into high-volume chronic therapeutic segments. In FY26, NATCO launched generic Semaglutide multi-dose injection vials in India, making it the first company to commercialize this affordable GLP-1 diabetes treatment. It also introduced India’s first generic Risdiplam for the treatment of Spinal Muscular Atrophy (SMA), lowering therapy costs for pediatric and adult rare-disease patients.

• R&D Allocation: Annual research spending reached ₹4,086 Million in FY26, representing 10.5% of standalone total income.
• US Pipeline Assets: The company maintains 28 Paragraph IV filings in the United States, featuring over 20 First-to-File (FTF) opportunities.
• Agrochemical Demerger: The Board of Directors approved the demerger of Natco Crop Health Sciences Limited to unlock independent business value.

Business Segments

NATCO Pharma Limited operates two distinct business segments: Pharmaceuticals and Agrochemicals. The pharmaceutical segment constitutes the primary revenue driver, encompassing export formulations, domestic formulations, and backward-integrated API manufacturing. The agrochemical business operates through the Crop Health Sciences (CHS) division, targeting pest and disease management through synthetic organic chemistry and pheromone technology.

Disclosed Segment & Divisional Revenue Breakdown

Source: NATCO Pharma Limited Annual Report 2025-26.

The revenue data highlights NATCO’s planned diversification away from concentrated single-geography dependence. United States formulation exports generated ₹23,810 Million, contributing 54.41% of total revenue in FY26 compared to ₹31,487 Million in FY25, directly reflecting the expected reduction in Lenalidomide exclusivity volumes. Concurrently, the Crop Health Sciences division expanded from ₹606 Million in FY25 to ₹1,382 Million in FY26, achieving a 128.05% year-on-year revenue increase through deeper market penetration of Chlorantraniliprole (CTPR) combinations.

Consolidated Revenue Contribution (FY 2025-26)
┌─────────────────────────────────────────────────────────┐
│ United States Formulations: 54.41%                      │
│ Brazil Formulations: 6.57%                              │
│ Canada Formulations: 5.75%                              │
│ Crop Health Sciences: 3.16%                             │
│ Domestic Formulations, APIs & RoW: 30.11%               │
└─────────────────────────────────────────────────────────┘

Pharmaceuticals Segment

The pharmaceuticals business operates on an integrated model spanning chemical research, API synthesis, clinical bioequivalence trials, and formulation manufacturing.

• Supply Chain Integration: The internal API pipeline supplies critical starting inputs, mitigating raw material bottlenecks and protecting product margins.
• Regulatory Compliance: Manufacturing operations adhere to cGMP standards verified by international regulatory bodies, including the USFDA, Health Canada, ANVISA, and the WHO.
• Therapeutic Focus: Product pipelines target complex chemistries, high-potency molecules, and cytotoxic formulations with limited generic competition.

Export Formulations Division

Export formulations serve as NATCO’s largest revenue component. The division utilizes a dual model: direct commercial front-ends in select countries alongside joint development and distribution partnerships in highly litigious jurisdictions such as the United States. Under this framework, NATCO manages laboratory development, chemical synthesis, regulatory filings, and manufacturing, while commercial partners oversee regional distribution and legal proceedings.

• US Asset Base: The company maintains more than 45 approved Abbreviated New Drug Applications (ANDAs) and 25+ Paragraph IV pipeline assets.
• Approvals Velocity: During FY26, the USFDA approved five NATCO ANDAs (one final and four tentative).
• Filing Rate: Four new ANDA submissions were completed in the United States over the same financial year.

Domestic Formulations Business

The domestic formulation business is organized into four specialized therapeutic divisions designed to supply branded generic therapies across Indian healthcare institutions:

Oncology Division

Serving as an early cornerstone of NATCO’s domestic presence, this division supplies targeted therapies for hematological malignancies and solid tumors. Its pipeline encompasses treatments for lung, breast, and liver cancers, manufactured in dedicated containment facilities.

Pharma Specialty Division

Operated through two commercial subdivisions, Dynami and Hygeia:

• Dynami: Focuses on hospital anti-infectives, supplying antibacterials, antifungals, and antivirals to intensivists, pulmonologists, and bone marrow transplant units.
• Hygeia: Addresses gastroenterology, hepatology, orthopedics, and pediatric neurology. The unit commercializes therapies for chronic Hepatitis B and C, oral bisphosphonates, and generic Risdiplam for Spinal Muscular Atrophy.

Cardiology Division

Established in 2017, this division focuses on cardiovascular therapies. The portfolio includes Novel Oral Anticoagulants (NOACs), antihypertensives, and antiplatelet agents, including first-to-market generic versions of Apixaban and Dabigatran.

Diabetology Division

This division offers metabolic solutions encompassing DPP-4 inhibitors and SGLT2 inhibitors. In FY26, it expanded access to peptide therapies by introducing India’s first generic Semaglutide in multi-dose vials and pre-filled pen formats.

Domestic Therapeutic Architecture
┌─────────────────────────────────────────────────────────┐
│ Oncology: Targeted therapies & cytotoxic oral/injectables│
│ Dynami Specialty: Critical anti-infectives & hospital care│
│ Hygeia Specialty: Hepatology, orthopedics, rare disease │
│ Cardiology: Novel Oral Anticoagulants & cardioprotectives│
│ Diabetology: GLP-1 receptor agonists & oral antidiabetics│
└─────────────────────────────────────────────────────────┘

Active Pharmaceutical Ingredients (API) Division

The API business serves a dual purpose: supporting internal formulation manufacturing through backward integration and generating merchant sales to pharmaceutical companies globally. Operating out of specialized chemical production centers in Mekaguda and Chennai, the division handles complex multi-step organic synthesis, peptide synthesis, containment of cytotoxic APIs, and process safety evaluations.

• Portfolio Breadth: The business holds more than 50 Drug Master Files (DMFs), with 49 active DMF filings spanning oncology, CNS, pain management, and cardiovascular therapies.
• Global Regulatory Approvals: The manufacturing infrastructure holds approvals from the USFDA, Germany’s Hamburg Health Authority, Australia’s TGA, Japan’s PMDA, South Korea’s KFDA, Mexico’s COFEPRIS, and the EDQM.
• Audit Validations: During FY26, the Chennai API facility completed a USFDA regulatory audit and received an Establishment Inspection Report (EIR).

Agrochemicals Segment (Crop Health Sciences Division)

Established in 2019, the Crop Health Sciences (CHS) division applies NATCO’s synthetic organic chemistry expertise to agricultural crop protection. Operating dedicated technical and formulation facilities in Attivaram, Andhra Pradesh, the unit develops pest management solutions aimed at improving crop productivity.

• Flagship Insecticide: The division manufactures Chlorantraniliprole (CTPR) and proprietary combination products across key agrarian states.
• Green Chemistry: NATCO commercialized an indigenous pheromone-based mating disruption product to manage pink bollworm infestations in cotton.
• Portfolio Scope: Products include insecticides, herbicides, bio-stimulants, and crop growth promoters.
• Demerger Approved: On March 24, 2026, the Board approved a Scheme of Arrangement to demerge the agrochemicals undertaking into Natco Crop Health Sciences Limited.
• Share Entitlement: Existing shareholders are entitled to receive one share of Natco Crop Health Sciences Limited (₹2 face value) for every one share held in NATCO Pharma Limited.

History and Evolution

From its founding in Hyderabad in 1981, NATCO’s history reflects a consistent focus on difficult-to-make chemistries, regulatory litigation, and international asset expansion.

Chronological Evolution: 1981 to 2026
┌──────┬─────────────────────────────────────────────────┐
│ 1981 │ Incorporated in Hyderabad, Telangana            │
│ 1983 │ Operations begin at Kothur manufacturing plant  │
│ 1986 │ Operations begin at Nagarjuna Sagar facility    │
│ 1993 │ Chemical division started at Mekaguda           │
│ 1997 │ NATCO Research Centre (NRC) established         │
│ 2003 │ Oncology division launched with VEENAT          │
│ 2006 │ First finished dosage facility in Dehradun      │
│ 2007 │ First commercial ANDA launched in the US        │
│ 2008 │ First Paragraph IV patent challenge filed in US │
│ 2010 │ Cytotoxic API facility opens in Chennai         │
│ 2011 │ Natcofarma do Brasil established in Brazil      │
│ 2012 │ NATCO Pharma Asia established in Singapore      │
│ 2013 │ NATCO Pharma Canada founded in Toronto          │
│ 2014 │ NATCO Pharma Australia established              │
│ 2015 │ Generic Sofosbuvir launched; Guwahati opens     │
│ 2016 │ Generic Oseltamivir capsules launched in the US │
│ 2017 │ Glatiramer Acetate launched; Cardio-Diabetology │
│ 2018 │ Denopsy and generic Posaconazole launched       │
│ 2019 │ Crop Health Sciences launched; Vizag opens      │
│ 2020 │ Visakhapatnam site receives USFDA approval      │
│ 2021 │ Acquisition of Dash Pharmaceuticals (USA)       │
│ 2022 │ CTPR agrochemicals & generic Revlimid launched  │
│ 2023 │ Subsidiaries in Indonesia, UK, and Colombia     │
│ 2024 │ Strategic investments in eGenesis and Cellogen  │
│ 2025 │ 34.88% stake acquired in Adcock Ingram          │
│ 2026 │ Semaglutide & Risdiplam; Adcock stake at 49%    │
└──────┴─────────────────────────────────────────────────┘

The company commenced industrial formulation manufacturing at Kothur in 1983, followed by a second production facility at Nagarjuna Sagar in 1986. Recognizing the importance of active raw material availability, the group launched its chemical synthesis division at Mekaguda in 1993.

To build internal product development capabilities, the group opened the NATCO Research Centre (NRC) at Sanathnagar, Hyderabad, in 1997. This laboratory network supported the launch of the domestic oncology division in 2003, headlined by VEENAT (generic Imatinib Mesylate), which lowered the cost of treating chronic myeloid leukemia in India.

International expansion accelerated in 2006 with the commissioning of the Dehradun finished dosage facility, leading to NATCO’s first commercial ANDA launch in the United States in 2007. In 2008, NATCO filed its first US Paragraph IV patent challenge, establishing its specialty legal-regulatory approach.

• High-Potency Assets: The company expanded cytotoxic active ingredient manufacturing in 2010 with an organics facility in Chennai.
• Subsidiary Front-Ends: Direct commercial structures were formed in Brazil (2011), Singapore (2012), Canada (2013), and Australia (2014).
• Infectious Disease Access: NATCO introduced generic Sofosbuvir in India and Nepal for Hepatitis C in 2015, supported by new capacity at Guwahati, Assam.
• First-to-Market Milestones: In 2016, NATCO and its partner introduced the first generic version of Oseltamivir Phosphate capsules in the United States.
• Complex Injectables: The company commercialized Glatiramer Acetate injection and Liposomal Doxorubicin in the United States in 2017.

Between 2019 and 2022, NATCO commercialized its Visakhapatnam formulation site (USFDA-approved in 2020) and entered agrochemicals via the Crop Health Sciences division. In 2021, it acquired Dash Pharmaceuticals LLC, establishing a direct US commercial front-end (renamed NATCO Pharma USA LLC).

In 2022, NATCO launched generic Revlimid (Lenalidomide) in the US and introduced CTPR insecticides across India. Between 2024 and 2026, the company broadened its pipeline through investments in cell and gene therapy, xenotransplantation, the acquisition of a 49% stake in Adcock Ingram, and first-to-market Indian launches of Semaglutide and Risdiplam.

Products and Services

NATCO’s commercial operations focus on high-barrier oral solids, cytotoxic parenterals, and agricultural inputs.

Therapeutic Families & Specialty Segments

Oncology & Immunomodulatory Therapeutics

Oncology products represent the foundation of NATCO’s specialized product catalog:

• Lenalidomide: An immunomodulatory agent for multiple myeloma. The product drove substantial export revenue under US market entry terms and holds leading generic volume share in Canada.
• Pomalidomide: An analogue of thalidomide commercialized in the United States in FY26 for relapsed or refractory multiple myeloma.
• Everolimus: An mTOR kinase inhibitor. NATCO commercialized a 1mg dosage in the US in FY26 and has served as Brazil’s sole supplier for four consecutive years.
• Carfilzomib: A proteasome inhibitor developed for multiple myeloma, manufactured as a lyophilized injectable powder.
• Liposomal Doxorubicin: An encapsulated cytotoxic formulation targeting ovarian cancer, Kaposi’s sarcoma, and multiple myeloma.
• Imatinib Mesylate: A targeted Bcr-Abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

Metabolic & Diabetology Therapeutics

• Semaglutide: A glucagon-like peptide-1 (GLP-1) receptor agonist for Type 2 Diabetes Mellitus and chronic weight management. In FY26, NATCO launched generic Semaglutide multi-dose vials in India, with pre-filled pen formats in development.
• Oral Antidiabetics: Portfolio of DPP-4 and SGLT2 inhibitor formulations distributed through the Indian Diabetology division.

Rare Disease & Specialized Neurological Formulations

• Risdiplam: An SMN2 splicing modifier targeting Spinal Muscular Atrophy (SMA). NATCO introduced the first generic formulation in India in FY26.
• Denopsy (Teriflunomide): An oral pyrimidine synthesis inhibitor approved for relapsing forms of multiple sclerosis.
• Bosentan: An endothelin receptor antagonist commercialized in the United States in FY26 for pulmonary arterial hypertension.

Anticoagulant & Cardiovascular Medicines

• Apixaban: A direct oral Factor Xa inhibitor for deep vein thrombosis, pulmonary embolism, and stroke prevention in non-valvular atrial fibrillation. First to launch in India and Brazil.
• Dabigatran: A direct thrombin inhibitor providing alternatives to traditional vitamin K antagonists.

Anti-Infectives & Viral Therapeutics

• Oseltamivir Phosphate: A neuraminidase inhibitor for Influenza A and B treatment and prophylaxis, holding leading generic volume share in Canada and China.
• Sofosbuvir & Combinations: Direct-acting antiviral agents targeting chronic Hepatitis C, distributed across India, Nepal, and emerging markets.
• Posaconazole: A triazole antifungal agent manufactured in both oral solid and injectable forms for immunocompromised oncology patients.

Agrochemicals & Crop Protection Solutions

• Chlorantraniliprole (CTPR): An anthranilic diamide insecticide providing broad-spectrum control against lepidopteran pests across key Indian crops.
• Pink Bollworm Pheromones: Integrated pest management technology utilizing pheromone release to disrupt mating cycles in cotton farming.
• Herbicides and Plant Bio-stimulants: Formulations designed to optimize soil yields and manage weed pressure.

Pipeline Focus Areas
┌─────────────────────────────────────────────────────────┐
│ Peptides & Oligonucleotides: Solid-phase synthesis      │
│ Novel Drug Delivery: Liposomes & nanoparticle isolation │
│ Hot Melt Extrusion: Solubility enhancement platforms    │
│ Para IV Pipeline: 28 patent challenges in the US        │
│ Cell & Gene Therapy: Strategic biotechnology investments│
└─────────────────────────────────────────────────────────┘

Research & Product Pipeline – United States

NATCO’s primary value creation strategy relies on Paragraph IV certifications under the Hatch-Waxman Act, targeting First-to-File (FTF) generic exclusivity.

Source: NATCO Pharma Limited Annual Report 2025-26.

The pipeline table demonstrates NATCO’s focus on high-barrier filings. The portfolio features 28 Paragraph IV filings, including over 20 FTF opportunities, with 14 ANDAs holding tentative or final USFDA approval.

• Metabolic Filings: The pipeline includes generic versions of Ozempic and Wegovy across pen devices and dosage strengths.
• Oncology Coverage: Targeted therapies such as Olaparib, Ibrutinib, and Erdafitinib aim to secure generic market share upon patent expiries.
• Patent Protection: The company has filed 329 international patents (217 granted) and 299 domestic patents (116 granted) to protect its manufacturing processes.

Brand Portfolio

NATCO commercializes products through its own corporate brands and, following its associate acquisition, through Adcock Ingram’s established OTC and consumer brands in Southern Africa.

Selected Brand Portfolio
┌─────────────────────────────────────────────────────────┐
│ Oncology: VEENAT (Imatinib Mesylate)                    │
│ Hepatology: VELPANAT (Sofosbuvir + Velpatasvir)         │
│ Neurology: DENOPSY (Teriflunomide)                      │
│ Consumer Health: PANADO, BIOPLUS, CITRO-SODA            │
│ Specialized Care: EPIMAX, ALLERGEX, SYNALEVE, PLUSH     │
└─────────────────────────────────────────────────────────┘

NATCO Domestic & International Branded Portfolio

• VEENAT: Generic Imatinib Mesylate, launched in 2003 as NATCO’s flagship oncology brand for chronic myeloid leukemia.
• VELPANAT: Fixed-dose combination of Sofosbuvir and Velpatasvir, prescribed for pan-genotypic chronic Hepatitis C infections.
• DENOPSY: Oral formulation of Teriflunomide for multiple sclerosis management, launched domestically in 2018.

Adcock Ingram Brand Portfolio (South African Associate)

Adcock Ingram holds leading market positions in South Africa across prescription, OTC, hospital, and consumer health channels. In FY26, its top ten brands generated approximately one-third of its US$592 Million in total revenue:

• Panado: Analgesic and antipyretic brand in South Africa, available in pediatric syrups, effervescent tablets, and capsules.
• Epimax: Dermatological range of emollient creams and moisturizers for dry skin, eczema, and psoriasis.
• Allergex: Antihistamine brand indicated for allergic rhinitis, urticaria, and seasonal allergies.
• Adco Mayogel: Gastrointestinal antacid suspension for heartburn, indigestion, and acid reflux.
• Bioplus: Physical energy tonic, syrup, and effervescent formulation targeting fatigue and physical recovery.
• Citro-Soda: Urinary alkalinizer and gastric antacid used for heartburn relief and urinary tract discomfort.
• Synaleve: Prescription analgesic capsules formulated for moderate to severe acute pain.
• Plush: Female hygiene and intimate care product portfolio.
• Broncleer: Cough syrup brand distributed across Southern African regional pharmacies.

Geographical Presence

NATCO ships products to more than 50 countries, supported by international subsidiaries, joint ventures, and distribution partnerships.

Geographic Presence & Manufacturing Network
┌─────────────────────────────────────────────────────────┐
│ United States: NATCO Pharma USA LLC                     │
│ Canada: NATCO Pharma (Canada) Inc.                      │
│ Brazil: NatcoFarma do Brasil Ltda.                      │
│ South Africa: Adcock Ingram Holdings (49% associate)   │
│ Southeast Asia: Singapore, Philippines, Indonesia       │
│ Indian Facilities: Telangana, Andhra, Assam, Tamil Nadu │
└─────────────────────────────────────────────────────────┘

Disclosed Regional Market Revenues

Source: NATCO Pharma Limited Annual Report 2025-26.

Operational Footprint Across Key Geographies

United States Market

The United States remains NATCO’s largest revenue market, generating ₹23,810 Million in FY26. Operations combine direct marketing through NATCO Pharma USA LLC with distribution alliances for high-value Paragraph IV filings. During the year, the company launched Pomalidomide, Everolimus (1mg), and Bosentan, while advancing 28 Paragraph IV patent challenges.

Brazil Market

Operating via NatcoFarma do Brasil Ltda., the group recorded ₹2,875 Million in FY26 revenue. NATCO remained the sole supplier of Everolimus in Brazil for the fourth consecutive year, while launching Carfilzomib, Eltrombopag, and Apixaban. Commercialization leverages a mix of direct sales, out-licensing, and public healthcare tenders.

Canada Market

Headquartered in Toronto, wholly owned subsidiary NATCO Pharma Canada Inc. generated ₹2,517 Million in FY26 revenue. The subsidiary ranks among the top 10 generic pharmaceutical companies by sales revenue in Canada, holding leading volume share in generic Lenalidomide and Oseltamivir. It manages a commercial base of 20+ products with 20+ filings pending, targeting six to eight new regulatory submissions annually.

South African Market

Through wholly owned subsidiary NATCO Pharma South Africa Proprietary Limited, NATCO acquired a 35.75% interest in Adcock Ingram Holdings Proprietary Limited in November 2025, increasing it to 49% in July 2026. Adcock Ingram operates three South African manufacturing plants and a 49% joint venture in Bangalore, India. It generated US$592 Million in revenue and US$57 Million in PAT for the year ended June 2026, giving NATCO an established commercial platform across Southern Africa.

Southeast Asia & Emerging Markets

• Singapore: NATCO Pharma Asia Pte Ltd manages commercial filings and holds Health Sciences Authority (HSA) approvals for specialty oncology products.
• Indonesia: Wholly owned subsidiary PT NATCO Lotus Farma manages localized registrations, supported by Indonesia’s national health insurance framework.
• Philippines: NATCO Lifesciences Philippines Inc. manages commercial distribution of hospital therapeutics.
• China: NATCO commercialized Oseltamivir capsules and oncology products Abiraterone and Gefitinib.
• MENA: Expanded public tender participation across Saudi Arabia, Algeria, and Egypt.

Profit and Loss

The Statement of Profit and Loss for the financial year ended March 31, 2026, reflects a planned normalization following peak Lenalidomide sales in the US.

Audited Profit and Loss Performance

Source: NATCO Pharma Limited Annual Report 2025-26.

Financial Statement Analysis

Consolidated total income reached ₹43,759 Million in FY26, down 8.53% from ₹47,840 Million in FY25. Consolidated EBITDA decreased 32.01% to ₹17,341 Million, yielding a 39.6% EBITDA margin compared to 53.3% in FY25. This variation resulted primarily from product mix shifts as Lenalidomide exclusivity tapered and R&D expenditures grew.

• Tax Provisions: Current tax provisions fell from ₹4,376 Million to ₹3,035 Million, alongside a deferred tax credit of ₹1,846 Million.
• Associate Accretion: Adcock Ingram contributed ₹466 Million in post-tax profit share between November 11, 2025, and March 31, 2026.
• Comprehensive Income: Total comprehensive income finished at ₹17,059 Million, supported by positive OCI of ₹2,874 Million.

Five-Year Net Profit & Margin Progression
┌──────┬──────────────────┬────────────┐
│ FY22 │ ₹1,700 Million   │ 8.3% PAT   │
│ FY23 │ ₹7,153 Million   │ 25.4% PAT  │
│ FY24 │ ₹13,883 Million  │ 33.6% PAT  │
│ FY25 │ ₹18,834 Million  │ 39.4% PAT  │
│ FY26 │ ₹14,185 Million  │ 32.4% PAT  │
└──────┴──────────────────┴────────────┘

Balance Sheet and Capital Structure

NATCO’s balance sheet reflects low leverage, a growing asset base, and sustained reinvestment of operating cash flow.

Disclosed Balance Sheet & Capital Indicators

Source: NATCO Pharma Limited Annual Report 2025-26.

Consolidated Net Worth expanded to ₹92,211 Million in FY26, up from ₹76,070 Million in FY25, driven by profit retention. Return on Capital Employed (ROCE) settled at 16.3%, and Return on Equity stood at 15.4%, reflecting capital additions across manufacturing facilities and international investments.

Five-Year Consolidated Net Worth Growth (₹ Million)
FY22: 42,636 
FY23: 48,738 
FY24: 58,531 
FY25: 76,070 
FY26: 92,211 

• Capital Adjustments: Shareholders approved an increase in authorized capital from ₹400 Million to ₹450 Million at the AGM on September 25, 2025.
• Borrowing Authority: Under Section 180(1)(c), the Board’s borrowing authority was increased to ₹10,000 Million above paid-up capital, free reserves, and securities premium.
• Credit Strength: ICRA maintained its “AA” long-term and “A1+” short-term credit ratings.

Board of Directors and Leadership Team

The Board of Directors comprises nine members with professional backgrounds across industrial engineering, organic chemistry, clinical medicine, banking, and governance.

Board Governance Structure
┌─────────────────────────────────────────────────────────┐
│ Executive Directors: 4 members (44.44%)                 │
│ Independent Non-Executive: 5 members (55.55%)           │
│ Board Gender Diversity: 11.11%                          │
│ Lead Independent Director: Sri D. Vijaya Bhaskar        │
└─────────────────────────────────────────────────────────┘

Board of Directors Profiles

Sri V. C. Nannapaneni – Chairman and Managing Director

Founder of NATCO Pharma Limited, Sri V.C. Nannapaneni has guided the group’s development for over 45 years. He holds a postgraduate degree in Pharmaceutical Administration from Long Island University, USA. His core areas of expertise include executive management, chemical technology, pharmaceutical industry knowledge, and global commerce.

Sri Rajeev Nannapaneni – Vice Chairman and Chief Executive Officer

Sri Rajeev Nannapaneni oversees corporate strategy, international business development, and operational execution. He holds a Bachelor’s degree in Quantitative Economics and History from Tufts University, Boston, USA. His leadership covers Paragraph IV litigation, pipeline development, and M&A transactions, including the Adcock Ingram acquisition.

Sri P.S.R.K. Prasad – Director and Executive Vice President (Corporate Engineering Services)

Sri P.S.R.K. Prasad directs corporate engineering, infrastructure planning, and facility expansion projects. He holds a B.E. in Mechanical Engineering and brings technical expertise in regulatory-compliant plant design and automation.

Dr. D. Linga Rao – Director and President (Technical Affairs)

Dr. D. Linga Rao oversees pharmaceutical development, global regulatory affairs, quality assurance, and manufacturing compliance. He holds a Ph.D. in Chemistry and manages relationships with regulatory authorities such as the USFDA and Health Canada.

Sri D. Vijaya Bhaskar – Independent Director & Lead Independent Director

Sri D. Vijaya Bhaskar provides independent oversight and coordinates the independent director cadre. His background centers on corporate governance, regulatory frameworks, and commercial risk review. He serves as Chairman of the Nomination and Remuneration Committee and member of the Audit Committee.

Sri A.D.M. Chavali – Independent Director

A seasoned commercial banker and former Executive Director of Indian Overseas Bank, Sri A.D.M. Chavali brings extensive expertise in financial evaluation, credit risk, and statutory reporting. He sits on the Audit Committee, Nomination and Remuneration Committee, and Risk Management Committee.

Sri Lakshminarayana Bolisetty – Independent Director

Sri Lakshminarayana Bolisetty is a financial professional with expertise in corporate taxation, capital markets, and internal control systems. He serves as Chairman of the Audit Committee, leading reviews of financial disclosures and internal audit compliance.

Dr. Kantipudi Suma – Independent Director

Dr. Kantipudi Suma is a medical professional specializing in clinical medicine and public health administration. She contributes perspectives to corporate social responsibility, occupational health standards, and human capital governance.

Sri Nitin Jain – Independent Director

Sri Nitin Jain has practical expertise in operations, supply chain logistics, and commercial administration. He serves as a member of the Audit Committee and ESG Committee, monitoring operating controls and sustainability initiatives.

Board Committee Attendance and Composition

Source: NATCO Pharma Limited Annual Report 2025-26.

Executive Management Team

• Amit Parekh: Chief Financial Officer (Appointed w.e.f. February 13, 2026, succeeding S.V.V.N. Appa Rao following his superannuation).
• Sadasiva Rao N: Executive Vice President – Corporate Affairs, Legal & Secretarial, Estate Management.
• Rajesh Chebiyam: Executive Vice President – Crop Health Sciences.
• Kalakuntla Srinivas Rao: Executive Vice President – Pharma Division (Appointed w.e.f. February 12, 2026).
• Lakshminarayana A: Senior Vice President – HR & OD.
• Sunil Kotaru: Senior Vice President – Supply Chain Management.
• Suryanarayana Reddy Matli: Senior Vice President – Quality Assurance.
• Imtiyaz Basade: Senior Vice President – R&D.
• Bhimrao Dattu Jadhav: Senior Vice President – Operations (Formulations).
• Yarramshetty Krishna Rao: Senior Vice President – Operations.
• Dr. Rampalli Sriram: Senior Vice President – CRD.
• Sandeep Kumar: Senior Vice President – QA.
• Gnanadeva Chalapathy Gudipati: Senior Vice President – Analytical R&D (w.e.f. July 06, 2026).
• Venkat Ramesh Ch.: Company Secretary & Compliance Officer.

Subsidiaries, Associates, and Joint Ventures

NATCO conducts international business operations through thirteen subsidiaries, two step-down subsidiaries, and one associate company.

Subsidiary Financial Details (Form AOC-1)

Source: NATCO Pharma Limited Annual Report 2025-26.

Associate Company Performance

Source: NATCO Pharma Limited Annual Report 2025-26.

Profiles of Primary Subsidiaries and Associate

NatcoFarma do Brasil Ltda.

Headquartered in Brazil, this subsidiary generates the highest revenue among NATCO’s direct operating units, reporting ₹2,449.54 Million in turnover and ₹570.52 Million in PAT for FY26. It manages hospital and pharmacy distribution for oncology and specialty generic products across Brazil.

NATCO Pharma (Canada) Inc.

Based in Toronto, NATCO Pharma Canada Inc. generated ₹2,252.25 Million in turnover and ₹534.38 Million in PAT. Holding asset positions valued at ₹5,880.92 Million, the subsidiary distributes oral solid generics through Canadian pharmacy networks and hospital buying groups.

NATCO Pharma USA LLC

Formed following the acquisition of Dash Pharmaceuticals, this US-based entity recorded ₹2,057.52 Million in turnover during FY26. It provides NATCO with direct commercial distribution capabilities in the United States, supplementing its partnership models.

Adcock Ingram Holdings Proprietary Limited

Founded in 1890 and headquartered in Midrand, Johannesburg, Adcock Ingram is South Africa’s second-largest pharmaceutical manufacturer by private market share. The business operates four core divisions: Prescription, OTC, Hospital/Critical Care, and Consumer Healthcare.

• Manufacturing Infrastructure: Adcock operates three manufacturing sites in South Africa, including one of the Southern Hemisphere’s largest liquids plants in Clayville (12 million liters annually) and an IV fluids facility in Aeroton.
• Indian Operations: Adcock owns a 49% stake in a joint venture operating two manufacturing plants in Bangalore, India.
• Transaction Mechanics: NATCO acquired 34.88% through NPSA in November 2025 for ~ZAR 4.0 Billion (~US$226 Million) and delisted Adcock from the JSE[cite: 1]. An additional 13.25% stake acquired in July 2026 for ZAR 1.81 Billion (~US$111 Million) brought total ownership to 49%.

Other Strategic Investments

NATCO has deployed capital into early-stage biotechnology and novel drug development platforms to access emerging therapeutic modalities.

Source: NATCO Pharma Limited Annual Report 2025-26.

Physical Properties and Manufacturing Facilities

NATCO operates nine industrial manufacturing facilities across India, supported by dedicated research hubs and international manufacturing sites via its associate.

Industrial Manufacturing Map
┌───────────────────────┬─────────────────────────────────┐
│ Finished Formulations │ Kothur, Telangana               │
│                       │ Nagarjuna Sagar, Telangana      │
│                       │ Visakhapatnam, Andhra Pradesh   │
│                       │ Dehradun, Uttarakhand           │
│                       │ Guwahati, Assam                 │
├───────────────────────┼─────────────────────────────────┤
│ Active Ingredients    │ Mekaguda, Telangana             │
│                       │ Chennai, Tamil Nadu             │
├───────────────────────┼─────────────────────────────────┤
│ Agrochemicals         │ Attivaram, Andhra (Technical)   │
│                       │ Attivaram, Andhra (Formulations)│
├───────────────────────┼─────────────────────────────────┤
│ Corporate & Research  │ Banjara Hills & Sanathnagar     │
└───────────────────────┴─────────────────────────────────┘

Pharmaceutical Formulation Facilities

Kothur Facility (Telangana)

NATCO’s foundational manufacturing center, operational since 1983, specializes in oral solid dosage forms (tablets and capsules). In FY26, the company installed a liquid capsule filling line with an annual capacity of 75 lakh capsules. The plant completed a USFDA audit during the reporting year and received an Establishment Inspection Report.

Nagarjuna Sagar Facility (Telangana)

Operational since 1986, this site manufactures parenterals and oncological formulations. During FY26, the facility commissioned an oncology injectable plant with annual capacity of 10 lakh lyophilized vials and 39 lakh liquid vials, alongside a dedicated quality control laboratory.

Visakhapatnam Facility (Andhra Pradesh)

Located in an export-oriented economic zone, this site began commercial manufacturing in 2019 and received USFDA approval in 2020. In FY26, NATCO commissioned a 1,200-liter granulation line capable of producing 250 million tablets annually, along with a 2 L/hr spray dryer for specialized drying applications.

Dehradun Facility (Uttarakhand)

Commissioned in 2006, this plant manufactures oral solid dosages catering to domestic institutional markets and regional distribution networks.

Guwahati Facility (Assam)

Operational since 2015, this facility provides finished dosage manufacturing redundancy and supports institutional supply agreements across Eastern India.

Active Pharmaceutical Ingredient (API) Facilities

Mekaguda Chemical Division (Telangana)

Commissioned in 1993, Mekaguda serves as NATCO’s primary organic synthesis and bulk active ingredient manufacturing hub. The site handles multi-stage chemical synthesis and peptide production, operating with USFDA clearance confirmed via an EIR in FY26.

Chennai Organics Facility (Tamil Nadu)

Operational since 2010 in Manali, Chennai, this facility is engineered for cytotoxic active substance manufacturing, high-potency molecules, and containment processing. The site holds certifications from global regulators, received an EIR from the USFDA in FY26, and holds a GreenCo-Gold Rating from the Confederation of Indian Industry (CII).

Crop Health Sciences Manufacturing Facilities

Attivaram Formulations Facility (Andhra Pradesh)

Dedicated to commercial agrochemical production, this site formulates liquid, granular, and wettable powder crop protection products, including CTPR insecticides.

Attivaram Technical Plant (Andhra Pradesh)

Dedicated to agricultural active ingredient synthesis, this chemical plant produces technical-grade active molecules for internal formulation and bulk supply.

Research, Corporate, and International Infrastructure

• NATCO Research Centre (Sanathnagar, Hyderabad): Operating since 1997, NRC houses process chemistry laboratories, flow chemistry units, analytical testing suites, and bioequivalence capabilities.
• Corporate Headquarters (Banjara Hills, Hyderabad): Serves as the global administrative, legal, and operational coordination center.
• Adcock Ingram Clayville Facility (South Africa): Features liquid manufacturing capacity of 12 million liters per annum and produces 400,000 kilograms of effervescent granules and powders.
• Adcock Ingram Aeroton Facility (South Africa): Critical care production center producing 33 million large-volume parenterals, 35 million small-volume parenterals, and 1 million blood bags annually.
• Bangalore Joint Venture (India): Two formulation plants operated by Adcock Ingram’s 49% Indian joint venture.

Founders and Executive Leadership

NATCO was founded by Sri V. C. Nannapaneni, who has directed the group’s long-term strategy for more than four decades. His operational approach prioritized complex, patent-challenged chemistries over volume-driven generics. This orientation facilitated early generic launches such as VEENAT in 2003, which reduced Indian chronic myeloid leukemia treatment costs.

Vice Chairman and CEO Sri Rajeev Nannapaneni has managed the company’s international commercialization and regulatory litigation strategies. He guided the company’s Paragraph IV filings in the United States and oversaw the acquisition of Adcock Ingram to build a diversified platform outside the US.

• Long-Term Financial Growth: Total corporate revenues increased from ₹4,613 Million in FY2010 to ₹43,759 Million in FY2026.
• Earnings Expansion: Net profits grew from ₹487 Million in FY2010 to ₹14,185 Million in FY2026.
• Executive Succession: CFO S.V.V.N. Appa Rao superannuated on February 12, 2026, succeeded by Amit Parekh on February 13, 2026, ensuring financial continuity.

Investments and Capital Expenditure Plans

NATCO’s capital allocation strategy focuses on internal R&D, specialized manufacturing upgrades, and equity investments in international markets.

Capital Expenditure Priorities
┌─────────────────────────────────────────────────────────┐
│ Internal R&D: ₹4,086 Million (10.5% standalone income)  │
│ Nagarjuna Sagar: Dedicated oncology injectable lines    │
│ Visakhapatnam: High-capacity granulation & spray drying │
│ Kothur: Automated liquid capsule filling lines          │
│ Decarbonization: On-site solar & boiler electrification │
└─────────────────────────────────────────────────────────┘

R&D expenditure reached ₹4,086 Million in FY26, representing 10.5% of standalone total income and 11.4% of standalone operational revenue, compared to ₹3,733 Million (9.1%) in FY25. Management maintains a long-term research budget target of 6% to 8% of total revenue to support complex generic ANDAs, peptides, and oligonucleotide platforms.

Five-Year R&D Investment Record
┌──────┬──────────────────┬─────────────────────────────┐
│ FY22 │ ₹2,267 Million   │ 12.8% of Standalone Income  │
│ FY23 │ ₹1,959 Million   │ 8.3% of Standalone Income   │
│ FY24 │ ₹2,694 Million   │ 7.5% of Standalone Income   │
│ FY25 │ ₹3,733 Million   │ 9.1% of Standalone Income   │
│ FY26 │ ₹4,086 Million   │ 10.5% of Standalone Income  │
└──────┴──────────────────┴─────────────────────────────┘

Manufacturing investments completed during FY26 included the oncology injectable facility at Nagarjuna Sagar, granulation lines at Visakhapatnam, and liquid capsule machinery at Kothur. Environmental capital expenditures included the installation of a 565 kW solar facility and a planned 1.5 MW solar plant with electric boiler and battery systems at Mekaguda.

• African Investment: Capital deployment into Adcock Ingram totaled approximately ZAR 4.0 Billion (~US$226 Million) for the initial 34.88% stake, followed by ZAR 1.81 Billion (~US$111 Million) for the subsequent 13.25% tranche.
• Agrochemical Spin-Off: The demerger of Natco Crop Health Sciences Limited establishes an independent corporate vehicle capable of attracting outside investment to scale its agrochemical business.

Future Strategy and Growth Levers

Management has structured its forward operational strategy around five growth levers intended to stabilize revenue post-Lenalidomide and establish sustainable multi-region income streams.

Strategic Roadmap
┌─────────────────────────────────────────────────────────┐
│ FY27 Baseline Year: Establishing normalized earnings    │
│ Medium-Term Target: Double-digit growth across 2-3 years│
│ Five Market Pillars: India, US, Brazil, Canada, S. Africa│
│ Technology Focus: Peptides, oligos, NDDS platforms      │
│ Agrochemical Spin-Off: Independent capital allocation   │
└─────────────────────────────────────────────────────────┘

Geographic & Portfolio Diversification

Management has guided that FY27 will serve as a baseline year, with expectations for double-digit earnings growth over the subsequent two to three years. Growth will be driven by international operations across Brazil, Canada, and South Africa, reducing earnings concentration from US patent litigation.

Paragraph IV and Complex Generics Pipeline

NATCO continues to invest in Paragraph IV patent challenges in the United States, maintaining 28 active filings and over 20 First-to-File (FTF) assets. Key pipeline priorities include generic Semaglutide formulations (Ozempic and Wegovy), Carfilzomib, and Olaparib.

Advanced Therapeutic Platforms

The company is directing development resources toward complex modalities, including peptide synthesis, oligonucleotide development, and Novel Drug Delivery Systems (NDDS) such as liposomes and nanoparticles. In addition, strategic equity holdings in eGenesis, Cellogen, and Stero Therapeutics provide early exposure to xenotransplantation, CAR-T oncology, and rare disease therapies.

Agrochemical Spin-Off Execution

The demerger of the agrochemicals undertaking into Natco Crop Health Sciences Limited (NCHSL) provides a dedicated management team and capital structure for the business. The independent structure is designed to expand its CTPR insecticide footprint and broaden product lines into biological pest management and export markets.

Environmental Sustainability Roadmap

NATCO has committed to long-term resource stewardship goals, targeting a 35% renewable energy share across manufacturing operations by 2035 and net carbon neutrality by 2050. In FY26, renewable sources accounted for 26.31% of the group’s total energy mix.

Key Strengths

• Specialized Chemical Synthesis & Bioequivalence: Four decades of experience developing complex generics, high-potency APIs, cytotoxic molecules, and difficult peptide formulations.
• First-to-File Track Record: Established intellectual property expertise demonstrated by 28 US Paragraph IV filings and 20+ First-to-File opportunities.
• Regulatory Compliance Systems: Manufacturing facilities maintain consistent cGMP compliance, validated by USFDA EIRs received in FY26 for Mekaguda, Kothur, and Chennai, with zero product recalls during the year.
• Balance Sheet Resilience: A consolidated net worth of ₹92,211 Million, a 39.6% consolidated EBITDA margin, and ICRA AA/A1+ credit ratings provide balance sheet stability.
• Multi-Market Footprint: Commercial presence in over 50 countries, anchored by five operating hubs in India, the US, Brazil, Canada, and South Africa.
• Integrated Supply Chain: Internal API production secures active ingredients for commercial formulations, mitigating external supply risks.

Key Challenges and Risks

• Loss of Exclusivity Taper: The scheduled volume decline of generic Lenalidomide sales in the United States creates a transitional headwind, as reflected in lower FY26 export formulation revenue.
• United States Tariff Risks: Policy proposals in the United States introducing tariffs of up to 100% on patented medicines and bulk APIs create international trade uncertainty. While generics are currently exempt, a one-year review provision introduces regulatory risk.
• Domestic Price Controls: Expanding domestic oncology and specialty portfolios remain subject to National List of Essential Medicines (NLEM) price ceiling revisions and government procurement terms.
• Global Supply Chain Volatility: Ongoing geopolitical tensions in the Middle East and the Red Sea corridor create shipping delays, elevated freight costs, and raw material logistics challenges.
• High Research & Litigation Costs: Developing complex generic formulations, conducting clinical trials, and defending Paragraph IV patent challenges requires sustained capital commitments without guaranteed commercial returns.
• Environmental & Resource Dependencies: Bulk active chemical synthesis requires significant water and energy inputs, exposing operations to climate variations, regional water scarcity, and environmental compliance standards.

Conclusion and Strategic Outlook

NATCO Pharma Limited’s performance in FY 2025-26 demonstrates a deliberate transition from an exclusivity-dependent generic drug manufacturer to a diversified, multi-regional specialty pharmaceutical enterprise. While the normalization of US Lenalidomide sales moderated group revenue to ₹43,759 Million and PAT to ₹14,185 Million, the company generated an EBITDA margin of 39.6% and expanded its net worth to ₹92,211 Million.

The group’s operational foundation is supported by five geographic markets, an active Paragraph IV US pipeline, domestic market launches in GLP-1 and rare-disease therapies, and a 49% stake in South Africa’s Adcock Ingram. Supported by the approved spin-off of its Crop Health Sciences division, backward-integrated manufacturing plants, and a net-worth position exceeding ₹92,000 Million, NATCO is positioned to navigate FY27 as a baseline year while working toward sustained, double-digit growth.

Official Site: NATCO Pharma Limited